Drugs · acquisition-cost intelligence
Humulin N
Insulin human· ingredient insulin isophane· INSULIN HUMAN 100 [iU]/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$6.65
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other insulin isophane products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Novolin N | $5.23 | −$1.43 |
| Novolin 70/30 | $5.23 | −$1.43 |
| Humulin 70/30 | $6.65 | −$0.00560 |
Medicare Part D coverage · CY2026
On 177 plan formularies · typical tier 3
Prior auth 1% · Step therapy 0% · Quantity limit 30% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.